Valuation: Alkermes plc

Market Cap 9.19B 8.05B 7.41B 6.88B 13.07B 877B 13.24B 88.74B 34.54B 430B 34.51B 33.76B 1,492B P/E 2026 *
-146x
P/E 2027 * 92.3x
Enterprise Value 10.15B 8.89B 8.19B 7.6B 14.43B 968B 14.63B 98.03B 38.15B 475B 38.12B 37.29B 1,648B EV / Sales 2026 *
5.6x
EV / Sales 2027 * 5.23x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-1.17%
1 week+3.06%
Current month+3.06%
1 month+27.21%
3 months+63.54%
6 months+83.92%
Current year+92.99%
1 week 50.96
Extreme 50.96
55.67
1 month 42.19
Extreme 42.1907
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Technology Officer

19,000 0.0114%
06-11Sell

Director

-2,000 0.0012%
06-03Sell

Compliance Officer

-2,034 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%+3.06%+84.74%+80.72% 9.19B
-0.09%+6.05%+3.73%+10.25% 50.25B
-0.66%+0.03%+410.89%+609.91% 40.39B
+0.66%+6.75%+26.97%-4.86% 34.38B
-1.24%+7.37%+26.96%+61.41% 34.4B
-4.19%-1.84%+3.76%+32.17% 26.32B
+0.57%+0.85% - - 16.64B
-2.28%+2.89%+70.87%+131.35% 16.14B
+1.11%+1.31%+15.23%+22.42% 13.71B
+1.71%+5.69%+100.59%+100.59% 13.75B
Average -0.59%+3.76%+82.64%+116.00% 25.52B
Weighted average by Cap. -0.65%+4.10%+93.29%+136.23%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.46B 1.36B 2.58B 173B 2.61B 17.49B 6.81B 84.81B 6.8B 6.65B 294B 1.89B 1.66B 1.53B 1.42B 2.69B 180B 2.73B 18.27B 7.11B 88.59B 7.11B 6.95B 307B
Net income -61.83M -54.15M -49.88M -46.3M -87.92M -5.9B -89.11M -597M -232M -2.9B -232M -227M -10.04B 108M 95.01M 87.51M 81.23M 154M 10.35B 156M 1.05B 408M 5.08B 407M 398M 17.61B
Net Debt 961M 842M 775M 720M 1.37B 91.69B 1.39B 9.28B 3.61B 45.01B 3.61B 3.53B 156B 702M 614M 566M 525M 997M 66.92B 1.01B 6.77B 2.64B 32.85B 2.63B 2.58B 114B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
07/07/26 US$54.00 -2.08% 211,356
06/07/26 US$55.14 +1.03% 1,747,218
02/07/26 US$54.58 +5.53% 1,653,919
01/07/26 US$51.72 -1.29% 1,638,365
30/06/26 US$52.40 -0.26% 2,958,468
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
55.14USD
Average target price
50.19USD
Spread / Average Target
-8.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock